The nuclear factor κB (NF-κB) transcription factor regulates the expression of genes involved in cell survival and immune responses. We have identified a novel interferon (IFN)-activated signaling pathway that leads to NF-κB activation and demonstrate that a subset of IFN-stimulated genes and microRNAs that play key roles in cellular response to IFN is regulated by NF-κB. This review focuses on the IFN-induced NF-κB activation pathway and the role of NF-κB in the expression of IFN-induced coding and noncoding genes, antiviral activity and apoptosis, and the therapeutic application of IFN in cancer and infectious disease.
Get full access to this article
View all access options for this article.
References
1.
AuPY, YehWC. 2007. Physiological roles and mechanisms of signaling by TRAF2 and TRAF5. Adv Exp Med Biol, 597:32–47.
2.
BaeuerlePA. 1998. IkB-NFkB structures: at the interface of inflammation control. Cell, 95:729–731.
3.
BaeurelePA, BaltimoreD. 1988. IkB: a specific inhibitor of NFkB transcription factor. Science, 242:540–546.
4.
BartelDP. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116,2:281–297.
5.
BegAA, BaltimoreD. 1996. An essential role for NF-κB in preventing TNF-α-induced cell death. Science, 274:782–784.
6.
BonizziG, BebienM, OteroDC, Johnson-VroomKE, CaoY, VuD, JeggaAG, AronowBJ, GhoshG, RickertRC, KarinM. 2004. Activation of IKKalpha target genes depends on recognition of specific kappaB binding sites by RelB:p52 dimers. EMBO J, 23,21:4202–4210.
7.
ChanJA, KrichevskyAM, KosikKS. 2005. MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res, 65,14:6029–6033.
8.
Chawla-SarkarM, LindnerDJ, LiuYF, WilliamsBR, SenGC, SilvermanRH, BordenEC. 2003. Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis, 8,3:237–249.
9.
ChengCS, FeldmanKE, LeeJ, VermaS, HuangDB, HuynhK, ChangM, PonomarenkoJV, SunSC, BenedictCA, GhoshG, HoffmannA. 2011. The specificity of innate immune responses is enforced by repression of interferon response elements by NF-{kappa}B p50. Sci Signal, 4,161:ra11.
10.
ClarkJ, EdwardsS, FeberA, FlohrP, JohnM, GiddingsI, CrosslandS, StrattonMR, WoosterR, CampbellC, CooperCS. 2003. Genome-wide screening for complete genetic loss in prostate cancer by comparative hybridization onto cDNA microarrays. Oncogene, 22,8:1247–1252.
11.
DebA, HaqueSJ, MogensenT, SilvermanRH, WilliamsBR. 2001. RNA-dependent protein kinase PKR is required for activation of NF-kappa B by IFN-gamma in a STAT1-independent pathway. J Immunol, 166,10:6170–6180.
12.
DejardinE, DroinNM, DelhaseM, HaasE, CaoY, MakrisC, LiZW, KarinM, WareCF, GreenDR. 2002. The lymphotoxin-beta receptor induces different patterns of gene expression via two NF-kappaB pathways. Immunity, 17,4:525–535.
13.
DuZ, WeiL, MurtiA, PfefferSR, FanM, YangCH, PfefferLM. 2007. Non-conventional signal transduction by type 1 interferons: the NF-kappaB pathway. J Cell Biochem, 102,5:1087–1094.
14.
FoliniM, GandelliniP, LongoniN, ProfumoV, CallariM, PennatiM, ColecchiaM, SupinoR, VeneroniS, SalvioniR, ValdagniR, DaidoneMG, ZaffaroniN. 2010. miR-21: an oncomir on strike in prostate cancer. Mol Cancer, 9:12.
15.
JoplingCL, YiM, LancasterAM, LemonSM, SarnowP. 2005. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science, 309,5740:1577–1581.
16.
KarinM. 2006. Nuclear factor-kappaB in cancer development and progression. Nature, 441,7092:431–436.
17.
LiQ, WithoffS, VermaIM. 2005. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol, 26,6:318–325.
18.
LimLP, LauNC, Garrett-EngeleP, GrimsonA, SchelterJM, CastleJ, BartelDP, LinsleyPS, JohnsonJM. 2005. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature, 433,7027:769–773.
19.
LofflerD, Brocke-HeidrichK, PfeiferG, StocsitsC, HackermullerJ, KretzschmarAK, BurgerR, GramatzkiM, BlumertC, BauerK, CvijicH, UllmannAK, StadlerPF, HornF. 2007. Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood, 110,4:1330–1333.
20.
MarrackP, KapplerJ, MitchellT. 1999. Type I interferons keep activated T cells alive. J Exp Med, 189:521–530.
21.
PedersenIM, ChengG, WielandS, VoliniaS, CroceCM, ChisariFV, DavidM. 2007. Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature, 449,7164:919–922.
22.
PfefferLM, KimJG, PfefferSR, CarriganDJ, BakerDP, WeiL, HomayouniR. 2004. The role of NF-kappaB in the antiviral action of interferon and interferon-regulated gene expression. J Biol Chem, 279,30:31304–31311.
23.
PfefferLM, MullersmanJE, PfefferSR, MurtiA, ShiW, YangCH. 1997. STAT3 as an adapter to couple phosphatidylinositol-3 kinase to the IFNAR-1 chain of the type I IFN receptor. Science, 276:1418–1420.
24.
PloeghHL. 2000. Immune and other responses to viral infections. Nutr Rev, 58,2 Pt 2:S25–S30discussion S63–S73.
25.
PomerantzJL, BaltimoreD. 2002. Two pathways to NF-kappaB. Mol Cell, 10,4:693–695.
26.
RaniMR, HibbertL, SizemoreN, StarkGR, RansohoffRM. 2002. Requirement of phosphoinositide 3-kinase and Akt for interferon-beta-mediated induction of the beta-R1 (SCYB11) gene. J Biol Chem, 277,41:38456–38461.
27.
RotheM, SarmaV, DixitVM, GoeddelDV. 1995. TRAF2-mediated activation of NF-kappa B by TNF receptor 2 and CD40. Science, 269,5229:1424–1427.
28.
Sarasin-FilipowiczM, KrolJ, MarkiewiczI, HeimMH, FilipowiczW. 2009. Decreased levels of microRNA miR-122 in individuals with hepatitis C responding poorly to interferon therapy. Nat Med, 15,1:31–33.
29.
ScagnolariC, ZingarielloP, VecchietJ, SelvaggiC, RacciattiD, TalianiG, RivaE, PizzigalloE, AntonelliG. 2010. Differential expression of interferon-induced microRNAs in patients with chronic hepatitis C virus infection treated with pegylated interferon alpha. Virol J, 7:311.
30.
SenftlebenU, CaoY, XiaoG, GretenFR, KrahnG, BonizziG, ChenY, HuY, FongA, SunSC, KarinM. 2001. Activation by IKKalpha of a second, evolutionary conserved, NF-kappa B signaling pathway. Science, 293,5534:1495–1499.
TenoeverBR, NgSL, ChuaMA, McWhirterSM, Garcia-SastreA, ManiatisT. 2007. Multiple functions of the IKK-related kinase IKKepsilon in interferon-mediated antiviral immunity. Science, 315,5816:1274–1278.
33.
UddinS, FishEN, SherDA, GardziolaC, WhiteMF, PlataniasLC. 1997. Activation of the phosphatidylinositol 3-kinase serine kinase by IFN-alpha. J Immunol, 158:2390–2397.
34.
Van AntwerpDJ, MartinSJ, KafriT, GreenDR, VermaIM. 1996. Suppression of TNF-α-induced apotosis by NF-κB. Science, 274:787–789.
35.
VestalDJ, JeyaratnamJA. 2011. The guanylate-binding proteins: emerging insights into the biochemical properties and functions of this family of large interferon-induced guanosine triphosphatase. J Interferon Cytokine Res, 31,1:89–97.
36.
WangC-Y, MayoMW, BaldwinAS.Jr. 1996. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-κB. Science, 274:784–787.
YangCH, MurtiA, BasuL, KimJG, PfefferLM. 2000. IFNalpha/beta promotes cell survival by activating NF-kappaB. Proc Natl Acad Sci U S A, 97:13631–13636.
39.
YangCH, MurtiA, PfefferLM. 1998. STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Natl Acad Sci U S A, 95:5568–5572.
YangCH, MurtiA, PfefferSR, KimJG, DonnerDB, PfefferLM. 2001. Interferonalpha/beta promotes cell survival by activating NF-kappaB through phosphatidylinositol-3 kinase and Akt. J Biol Chem, 276:13756–13761.
42.
YangCH, MurtiA, ValentineWJ, DuZ, PfefferLM. 2005b. Interferon alpha activates NF-kappaB in JAK1-deficient cells through a TYK2-dependent pathway. J Biol Chem, 280,27:25849–25853.
43.
YangCH, WeiL, PfefferSR, DuZ, MurtiA, ValentineWJ, ZhengY, PfefferLM. 2007. Identification of CXCL11 as a STAT3-dependent gene induced by IFN. J Immunol, 178,2:986–992.
44.
YangCH, YueJ, FanM, PfefferLM. 2010. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res, 70,20:8108–8116.
